AR073158A1 - Metodo y composicion para modular el crecimiento de celulas madre - Google Patents
Metodo y composicion para modular el crecimiento de celulas madreInfo
- Publication number
- AR073158A1 AR073158A1 ARP090100582A ARP090100582A AR073158A1 AR 073158 A1 AR073158 A1 AR 073158A1 AR P090100582 A ARP090100582 A AR P090100582A AR P090100582 A ARP090100582 A AR P090100582A AR 073158 A1 AR073158 A1 AR 073158A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxy
- composition
- modulate
- cycloalkyl
- stem cells
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004423 acyloxy group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 230000004069 differentiation Effects 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- 230000035755 proliferation Effects 0.000 abstract 3
- -1 prostaglandin compound Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
- C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Una composicion que comprende un compuesto de prostaglandina para modular la proliferacion y/o diferenciacion de las células madre en un sujeto mamífero. Una composicion que comprende un compuesto de prostaglandina para modular la proliferacion y/o la diferenciacion de células madre de un sujeto mamífero, en donde las células madre se ponen en contacto directo o indirecto con la composicion de la presente solicitud. Reivindicacion 1: Uso de un compuesto de prostaglandina representado por la formula (1) en donde L, M y N son átomo de hidrogeno, hidroxi, átomo de halogeno, alquilo inferior, hidroxialquilo (inferior), alcanoiloxi inferior u oxo, en donde al menos uno de L y M es un grupo distinto de hidrogeno, y el anillo de cinco miembros puede tener al menos un enlace doble; A es -CH3 o -CH2OH, -COCH2OH, -COOH o uno de sus derivados funcionales; B es enlace simple, -CH2-CH2-, -CH=CH-, -C:::C-, -CH2-CH2-CH2-, -CH=CH-CH2-, -CH2-CH=CH-, -C:::C-CH2- o -CH2-C:::C-: Z es R4-C=R5, R4=C-R5, C=O o enlace simple, en donde R4 y R5 son H, hidroxi, halogeno, alquilo inferior, alcoxi inferior o hidroxialquilo (inferior), en donde R4 y R5 no son hidroxi y alcoxi inferior al mismo tiempo; R1 es un residuo hidrocarbonado alifático bivalente inferior o medio saturado o insaturado, que no está sustituido o que está sustituido con halogeno, alquilo, hidroxi, oxo, arilo o grupo heterocíclico, y al menos uno de átomo de carbono en el hidrocarburo alifático está opcionalmente sustituido con oxígeno, nitrogeno o azufre; y Ra es un residuo hidrocarbonado alifático inferior o medio saturado o insaturado que no está sustituido o que está sustituido con halogeno, oxo, hidroxi, alquilo inferior, alcoxi inferior, alcanoiloxi inferior, cicloalquilo (inferior), cicloalquil (inferior)oxi, arilo, ariloxi, grupo heterocíclico o grupo heterocíclico-oxi; alcoxi inferior; alcanoiloxi inferior; cicloalquilo (inferior); cicloalquil (inferior)oxi; arilo; ariloxi; grupo heterocíclico; grupo heterocíclico-oxi, para preparar una composicion farmacéutica para modular la proliferacion y/o la diferenciacion de células madre en un sujeto mamífero.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2971308P | 2008-02-19 | 2008-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073158A1 true AR073158A1 (es) | 2010-10-20 |
Family
ID=40602552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100582A AR073158A1 (es) | 2008-02-19 | 2009-02-19 | Metodo y composicion para modular el crecimiento de celulas madre |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8871752B2 (es) |
| EP (2) | EP2656845A1 (es) |
| JP (1) | JP2011512323A (es) |
| KR (1) | KR20100119803A (es) |
| CN (2) | CN102014921A (es) |
| AR (1) | AR073158A1 (es) |
| AU (1) | AU2009216067B2 (es) |
| BR (1) | BRPI0907831A2 (es) |
| CA (1) | CA2715486A1 (es) |
| IL (1) | IL207652A0 (es) |
| MX (1) | MX2010009131A (es) |
| NZ (1) | NZ587348A (es) |
| RU (1) | RU2010138603A (es) |
| TW (1) | TW200942614A (es) |
| WO (1) | WO2009104807A1 (es) |
| ZA (1) | ZA201006125B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3533445A1 (en) * | 2009-03-19 | 2019-09-04 | Fate Therapeutics, Inc. | Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same |
| NZ596555A (en) * | 2009-05-27 | 2014-01-31 | Univ Osaka | Pharmaceutical composition comprising prostaglandin derivatives for use in modulating claudin mediated functions and in the treatment of dermatological disorders |
| US8569279B2 (en) | 2009-05-27 | 2013-10-29 | Sucampo Ag | Method for modulating claudin mediated functions |
| KR101171912B1 (ko) | 2010-11-29 | 2012-08-07 | 기아자동차주식회사 | 밸브브릿지 일체형 가변 밸브 액츄에이터 |
| CA2857640C (en) | 2011-12-02 | 2021-11-16 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
| WO2013082241A2 (en) | 2011-12-02 | 2013-06-06 | Fate Therapeutics, Inc. | Improved methods of treating ischemia |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| WO2014150602A1 (en) | 2013-03-15 | 2014-09-25 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
| US20140371304A1 (en) * | 2013-06-13 | 2014-12-18 | Sucampo Ag | Method for suppressing tumorigenicity of stem cells |
| EP4538365A3 (en) * | 2016-03-04 | 2025-07-30 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin e2 |
| US9918994B2 (en) | 2016-03-04 | 2018-03-20 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin E2 |
| CA3065945A1 (en) | 2017-06-09 | 2018-12-13 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for preventing or treating muscle conditions |
| RU2686718C1 (ru) * | 2018-03-12 | 2019-04-30 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1322749C (en) | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
| US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| US5221763A (en) | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| CA2039420C (en) | 1990-04-04 | 1996-12-10 | Ryuji Ueno | Treatment of cataract with 15-keto-prostaglandin compounds |
| DK0503887T3 (da) * | 1991-03-14 | 1996-09-16 | R Tech Ueno Ltd | Fremme af sårheling med 15-ketoprostaglandinforbindelser |
| CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| US5703108A (en) * | 1996-02-28 | 1997-12-30 | Pfizer Inc. | Bone deposition by certain prostaglandin agonists |
| PT857718E (pt) | 1996-06-10 | 2002-11-29 | Sucampo Ag | Antagonista da endotelina |
| CN1443070A (zh) | 2000-03-24 | 2003-09-17 | 苏坎波公司 | 包含15－酮基－前列腺素或其衍生物的编程性细胞死亡抑制组合物 |
| TWI384988B (zh) | 2005-01-27 | 2013-02-11 | Sucampo Ag | 處理中樞神經系統失常用之組成物 |
| JP4557288B2 (ja) * | 2005-01-28 | 2010-10-06 | アイシン・エィ・ダブリュ株式会社 | 画像認識装置及び画像認識方法、並びにそれを用いた位置特定装置、車両制御装置及びナビゲーション装置 |
| WO2006093348A2 (en) | 2005-03-04 | 2006-09-08 | Sucampo Ag | Method and composition for treating peripheral vascular diseases |
| US20060281818A1 (en) | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| AU2006326853B2 (en) | 2005-12-22 | 2012-02-16 | Es Cell International Pte Ltd | Direct differentiation of cardiomyocytes from human embryonic stem cells |
| ZA200808123B (en) | 2006-03-24 | 2010-03-31 | Childrens Medical Center | Method to modulate hematopoietic stem cell growth |
| EP2094839B1 (en) | 2006-12-08 | 2020-02-05 | University of Rochester | Expansion of hematopoietic stem cells |
| EP2114411A2 (en) | 2007-02-27 | 2009-11-11 | Sucampo AG | Composition and method for protecting mitochondria |
| FI20075417A0 (fi) | 2007-06-05 | 2007-06-05 | Marjo-Riitta Suuronen | Koostumuksia ja menetelmiä alkion kantasolujen kasvatukseen |
-
2009
- 2009-02-18 US US12/388,048 patent/US8871752B2/en not_active Expired - Fee Related
- 2009-02-19 CN CN200980114702XA patent/CN102014921A/zh active Pending
- 2009-02-19 TW TW098105222A patent/TW200942614A/zh unknown
- 2009-02-19 BR BRPI0907831A patent/BRPI0907831A2/pt not_active IP Right Cessation
- 2009-02-19 MX MX2010009131A patent/MX2010009131A/es not_active Application Discontinuation
- 2009-02-19 AR ARP090100582A patent/AR073158A1/es unknown
- 2009-02-19 WO PCT/JP2009/053474 patent/WO2009104807A1/en not_active Ceased
- 2009-02-19 CN CN201410464976.4A patent/CN104248638A/zh active Pending
- 2009-02-19 EP EP13178225.2A patent/EP2656845A1/en not_active Withdrawn
- 2009-02-19 JP JP2010533155A patent/JP2011512323A/ja not_active Ceased
- 2009-02-19 KR KR1020107021031A patent/KR20100119803A/ko not_active Ceased
- 2009-02-19 AU AU2009216067A patent/AU2009216067B2/en not_active Ceased
- 2009-02-19 CA CA2715486A patent/CA2715486A1/en not_active Abandoned
- 2009-02-19 EP EP09712320A patent/EP2303278A1/en not_active Withdrawn
- 2009-02-19 NZ NZ587348A patent/NZ587348A/en not_active IP Right Cessation
- 2009-02-19 RU RU2010138603/15A patent/RU2010138603A/ru not_active Application Discontinuation
-
2010
- 2010-08-17 IL IL207652A patent/IL207652A0/en unknown
- 2010-08-27 ZA ZA2010/06125A patent/ZA201006125B/en unknown
-
2014
- 2014-09-16 US US14/487,153 patent/US20150005381A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2656845A1 (en) | 2013-10-30 |
| MX2010009131A (es) | 2010-12-06 |
| AU2009216067B2 (en) | 2014-02-13 |
| US20090209643A1 (en) | 2009-08-20 |
| ZA201006125B (en) | 2011-05-25 |
| NZ587348A (en) | 2012-04-27 |
| AU2009216067A1 (en) | 2009-08-27 |
| EP2303278A1 (en) | 2011-04-06 |
| KR20100119803A (ko) | 2010-11-10 |
| RU2010138603A (ru) | 2012-03-27 |
| US20150005381A1 (en) | 2015-01-01 |
| CN102014921A (zh) | 2011-04-13 |
| IL207652A0 (en) | 2010-12-30 |
| CA2715486A1 (en) | 2009-08-27 |
| WO2009104807A1 (en) | 2009-08-27 |
| BRPI0907831A2 (pt) | 2017-04-11 |
| TW200942614A (en) | 2009-10-16 |
| US8871752B2 (en) | 2014-10-28 |
| CN104248638A (zh) | 2014-12-31 |
| JP2011512323A (ja) | 2011-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073158A1 (es) | Metodo y composicion para modular el crecimiento de celulas madre | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| CO6220952A2 (es) | Nuevos derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| UY27227A1 (es) | Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad | |
| AR072657A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| CO5611131A2 (es) | Derivados de 5-feniltiazol y su uso como inhibidores de pi3 cinasa | |
| AR111812A2 (es) | Compuestos y composiciones para el control de nematodos | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| AR069596A1 (es) | Regulador del crecimiento de plantas | |
| CO6341575A2 (es) | Combinaciones que comprenden metotrexato e inhibidores de dhodh | |
| ES2613538T3 (es) | Derivados de arilamida como bloqueadores de TTX-S | |
| CO6400139A2 (es) | Derivados de ciclopenta[c]pirool-2-carboxilatos, su preparación y su aplicación en terapéutica | |
| DOP2010000227A (es) | Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion terapeutica | |
| MX2018013175A (es) | Metodo de purificacion para celulas precursoras pancreaticas derivadas a partir de celulas madre pluripotentes y metodo de amplificacion para ellas. | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR079498A1 (es) | Derivados de 2-arilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| MX2009012885A (es) | Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR068367A1 (es) | Derivados de amidas con actividad fungicida | |
| AR057350A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia. composiciones farmaceuticas | |
| CO6150181A2 (es) | Compuesto 6-(bencilo sustituido con heterociclo)-4-oxoquinolina y su uso como inhibidor de integrasa vih | |
| AR079077A1 (es) | Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica de enfermedades mediadas por la tirosina quinasa | |
| PE20141579A1 (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |